Mi­rati is once again the cen­ter of buy­out ru­mors, and a ri­val's ad­comm pro­vides a boost

Mi­rati Ther­a­peu­tics is once again at­tract­ing buy­out in­ter­est, this time al­leged­ly from Sanofi, ac­cord­ing to a re­port from Bloomberg on Thurs­day. The biotech’s shares $MRTX surged by rough­ly 45% in re­sponse.

It’s far from the first time Mi­rati has emerged as a po­ten­tial takeover tar­get. Mer­ck re­port­ed­ly con­sid­ered ac­quir­ing the com­pa­ny back in 2021, per a re­port from Bio­Space at the time, as it looked to stave off the up­com­ing Keytru­da patent cliff. And Bloomberg pre­vi­ous­ly re­port­ed last year that un­named Big Phar­ma com­pa­nies were look­ing in­to a buy­out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA